DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

MARCH 26, 2025

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 J Card Fail.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

Circulation: Heart Failure

NOVEMBER 25, 2024

Spironolactone reduced HF events in some patients with HF with preserved ejection fraction, but the results were not generalizable to all patients with HF with preserved ejection fraction. The use of MRAs has been limited due to excessive concern about hyperkalemia.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

Cardiometabolic Health Congress

JULY 25, 2023

Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103